Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1431 • ACR Convergence 2023
Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results
Peter C. Taylor¹, Kurt de Vlam², Philip J. Mease³, Paul M. Peloso⁴, Dieter Wetzel⁵, Apinya Lertratanakul⁶, Nikolai Brun⁷, Brian Wiens⁸, Jan Brandt-Juergens⁹, Edit Drescher¹⁰, Eva Dokoupilova¹¹, Anna Rowińska-Osuch¹², Nadia Abdel-Kader Martin¹³ and Frank Behrens¹⁴, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University Hospitals Leuven, Leuven, Belgium, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁴ACELYRIN, INC., Naples, FL, ⁵toclinco GmbH, Freiburg im Breisgau, Germany, ⁶ACELYRIN, Chicago, IL, ⁷Affibody AB, Solna, Sweden, ⁸ACELYRIN, Inc., Half Moon Bay, CA, ⁹rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰Csolnoky Ferenc Hospital / Vital Medical Center Private Clinci, Veszprém, Hungary, ¹¹Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ¹²ETG Warszawa, Warsaw, Poland, ¹³Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany
Background/Purpose: Izokibep is a novel small protein IL-17A inhibitor, unique for its high IL-17A binding affinity, a small size at 18.6 kD and albumin binding…
Abstract Number: 1651 • ACR Convergence 2023
Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Esther Vicente Rabaneda¹, Pedro Martínez-Fleta², Ana Triguero-Martínez², Emilia Roy³, Miren Uriarte-Ecenarro⁴, Francisco Gutiérrez-Rodríguez⁴, Patricia Quiroga⁴, Ana Romero⁴, Nuria Montes², Laura Esparcia Pinedo², María Aranzazu Alfranca², Rosario Garcia-Vicuna⁵, Francisco Sánchez-Madrid², Isidoro González-Álvaro⁴ and Santos Castañeda⁵, ¹Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ²Division of Immunology, Hospital Universitario de La Princesa, Madrid, Spain, ³Division of Internal Medicine, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁵Hospital Universitario de la Princesa, Madrid, Spain
Background/Purpose: Previous published works have raised the concern that methotrexate (MTX) might have a negative effect on immune response upon vaccine administration. At the beginning…
Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Alyssa Howren¹, Eric Sayre², J. Antonio Avina-Zubieta³, Joseph Puyat¹, Deborah Da Costa⁴, Hui Xie⁵, Amit Gupta¹ and Mary De Vera¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Simon Fraser University, Richmond, BC, Canada
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
Abstract Number: 2237 • ACR Convergence 2023
Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice
Eva Galindez-Agirregoikoa¹, Diana Prieto-Peña², Maria Luz Garcia Vivar¹, Lucia Vega-Alvarez¹, Cristina Vergara³, Irati Urionaguena⁴, Consuelo Ramos-Giráldez⁵, Raquel Almodovar⁶, Beatriz Joven Ibáñez⁷, Rosario Garcia-Vicuna⁸, Vega Jovani⁹, Teresa González¹⁰, Àngels Martínez-Ferrer¹¹, Ana Urruticoechea Arana¹², Bryan Josue Flores Robles¹³, Cristina Campos Fernández¹⁴, Lilian Maria Lopez Nunez¹⁵, Joaquin Maria Belzunegui Otano¹⁶, Marina Pavia Pascual¹⁷, Esteban Rubio¹⁸, Angel Ramos-Calvo¹⁹, Noemi Busquets²⁰, Ana Pérez Gómez²¹, Francisco Miguel Ortiz Sanjuan²², Rafael Benito Melero-Gonzalez²³, Cristina Macía²⁴, María Ángeles Puche Larrubia²⁵, Jose Antonio Pinto Tasende²⁶, Cristina Fernandez²⁷, Maria Paz Martinez-Vidal²⁸, Jaime Calvo- Alén²⁹, Emma Beltran-Catalan³⁰, Mireia Moreno³¹, Silvia Pérez-Barrio³², iñigo Gorostiza Hormaeche¹ and Ricardo Blanco³³, ¹Basurto University Hospital, Bilbao, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴GALDAKAO-USANSOLO UNIVERSITY HOSPITAL, GERNIKA-LUMO, Spain, ⁵Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, ⁶Alcorcón Foundation University Hospital, Madrid, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ¹⁰Hospital General Universitario Gregorio Marañón, Madrid, Spain, ¹¹Hospital Universitario Dr Peset Valéncia, Valéncia, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Hospital Universitario San Pedro, Logroño, Spain, ¹⁴Hospital General Universitario Valencia, Valencia, Spain, ¹⁵Son llatzer, Palmanyola, Spain, ¹⁶University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁷Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁸Servicio Andaluz Salud, Sevilla, Spain, ¹⁹Complejo Hospitalario de Soria, Soria, Spain, ²⁰HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ²¹Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²²Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²³CHU Vigo, O Carballino, Spain, ²⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁵Department of Rheumatology, Reina Sofia University Hospital, Cordoba, Spain, ²⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁷Hospital Universitario San Juan de Alicante, Alicante, Spain, ²⁸Hospital Universitario San Juan Alicante, Alicante, Spain, ²⁹Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ³⁰HOSPITAL DEL MAR, Barcelona, Spain, ³¹Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³²Hospital Universitario de Basurto, Bilbao, Spain, ³³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: The EMA authorized Upadacitinib (UPA) in PsA in January 2021. UPA has shown efficacy in PsA refractory to anti-TNF in a clinical trial (RCT).…
Abstract Number: 2253 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast
Joseph Merola¹, Philip J. Mease², April W. Armstrong³, Vibeke Strand⁴, Thomas Lehman⁵, Jiyoon Choi⁶, Brandon Becker⁶, Yichen Zhong⁷, Matthew J. Colombo⁷, Diamant Thaçi⁸, Androniki Bili⁷ and Alice B. Gottlieb⁹, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁴Stanford University, Portola Valley, CA, ⁵Bristol Myers Squibb, Philadelphia, PA, ⁶Bristol Myers Squibb, Lawrenceville, NJ, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁹Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: As 41% of patients with psoriasis may be undiagnosed for psoriatic arthritis, treatments must relieve both dermatologic and musculoskeletal symptoms. Deucravacitinib (DEUC), an oral,…
Abstract Number: 072 • 2023 Pediatric Rheumatology Symposium
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: L02 • ACR Convergence 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Christopher Ritchlin¹, Laura Coates², Iain McInnes³, Philip J. Mease⁴, Joseph Merola⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Laure Gossec⁸, Alice Gottlieb⁹, Diamant Thaci¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Vish Shende¹¹, Jason Coarse¹² and Robert Landewé¹³, ¹University of Rochester Medical Center, Rochester, NY, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ³College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁶University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Sorbonne Universités, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Hôpital Pitié Salpêtrière, Rheumatology Department, Paris, France, Paris, France, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, ¹³Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, Netherlands
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ treatment has demonstrated superior efficacy in joints and…
Abstract Number: L04 • ACR Convergence 2022
Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Soumyaroop Bhattacharya³, Jeffrey Fox⁴, Ernest Meyer⁵, Brian Isett⁵, Riyue Bao⁶, Tullia Bruno⁶ and Christopher Ritchlin⁷, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, ⁴CMSR, University of Rochester Medical Center, Rochester, NY, ⁵UPMC Hillman Cancer Center, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Rochester Medical Center, Rochester, NY
Background/Purpose: A pivotal clinical characteristic of psoriatic arthritis (PsA) is disease manifestations in several domains (skin, entheses, joints, spine) and multiple domain involvement is prevalent,…
Abstract Number: 0377 • ACR Convergence 2022
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Maria Angeles Puche Larrubia¹, lourdes Ladehesa-Pineda², María Dolores López Montilla², Raquel Granados³, Eduardo Collantes⁴ and Clementina Lopez-Medina⁵, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 1021 • ACR Convergence 2022
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
Rebecca Haberman¹, Seungha Um², Sydney Catron¹, Eileen Lydon³, Malavika Attur², Andrea Neimann², Soumya Reddy⁴, Andrea Troxel¹, Samrachana Adhikari¹ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Langone, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex immune-mediated disease. Beyond its deleterious effects in the skin and joints, PsA can lead to decreased quality of…
Abstract Number: 1096 • ACR Convergence 2022
IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis
Renée Van der Cruyssen¹, Djoere Gaublomme¹, Emilie Dumas¹, Carolien Vlieghe¹, Flore Stappers², Julie Coudenys¹, Tine Decruy¹, Lars Vereecke¹, Eric Gracey¹ and Dirk Elewaut³, ¹VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: IL-23 mediated inflammatory diseases such as psoriasis and psoriatic arthritis are associated with bone loss in addition to more classical features such as skin…
Abstract Number: 1425 • ACR Convergence 2022
Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases
Ran Jin¹, Silvia Kruppert², Florian Scholz², Marc Hammer², Greg Kricorian¹, David Collier³ and Jonathan Kay⁴, ¹Amgen, Inc., Thousand Oaks, CA, ²IQVIA, Frankfurt, Germany, ³Amgen Inc., Simi Valley, CA, ⁴Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA
Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
Abstract Number: 1506 • ACR Convergence 2022
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Rikesh Chakradhar², Alexis Ogdie³, John Davis⁴, Tina Gunderson⁴, Cassondra Hulshizer⁴, Kerry Wright⁴, Megha M. Tollefson⁵, Ali Duarte-Garcia⁴, Delamo Bekele⁴, Hilal Maradit Kremers⁴, Floranne Ernste⁴ and Cynthia Crowson⁶, ¹Vanderbilt University, Nashville, TN, ²St. Christopher's Hospital, Philadelphia, ³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Eyota, MN
Background/Purpose: Psoriasis is a systemic inflammatory disorder associated with cardiometabolic and other comorbidities. Psoriasis frequently precedes development of psoriatic arthritis (PsA), and comorbidities in psoriasis…
Abstract Number: 1768 • ACR Convergence 2022
Sex-Related Differences in Healthcare Utilization in Patients with Inflammatory Arthritis: A Population-based Study
Sanjana Tarannum¹, Jessica Widdifield¹, C. Fangyun Wang², Sindhu R. Johnson³, Paula Rochon¹ and Lihi Eder⁴, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Delayed diagnosis of inflammatory arthritis (IA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA), is associated with joint damage and disability.…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].